Abstract 124P
Background
Carcinoma esophagus is a disease with dismal prognosis and even though treatment has evolved considerably, morbidity after surgery has remained a drawback. We intend to prospectively study the pattern of care for such patients at our centre, how it affects their subsequent quality of life (QoL) and the factors that influence these changes.
Methods
All patients who underwent curative esophagectomy for carcinoma esophagus from May,2017 to May,2019 were included in the study after obtaining informed consent. Patient characteristics, pre-op therapy, surgical details and final histopathology reports were collected. QoL was collected at pre-op, 1 and 6 months after surgery using FACT-E, OES 18 and OG 25 questionnaires. QoL analysis was done comparing the changes that occured after curative surgery with the baseline value.
Results
99 patients underwent curative esophagectomy during the study period. With a mean age of 58.8 and a male to female ratio of 3.54 : 1, 84/99 underwent surgery after NACT. Lower third and GE junction primary adenocarcinomas accounted for 72 % of cases. Totally minimally invasive McKeowns procedure was the most common surgery done (33%). 8 patients comprised the 30-day mortality with 5 patients having anastomotic leak. QoL analysis showed a dip in post-op QoL at 1 month, with improvement to baseline at 6 months, both in general functional scales, as well as symptom scales. The improvement in symptom scales assessed by OES 18 and OG 25 were found to be statistically significant ( p value < 0.05). Younger patients (<50 yrs) and females fared better during the post-op period. There was a trend to better QoL for patients who underwent minimally invasive procedures. Those patients who had post-op complications, had inferior QoL at 1 month, but later improved by 6 months.
Conclusions
Radical esophagectomy can be performed with achievable morbidity and mortality at high volume centres. Global HRQoL scores show a dip during immediate post-surgery period, but then picks up to even eclipse pre-op values. Post-op morbidity, as expected, adversely affects HRQoL, but once patients tide over the immediate period, they often do well as time passes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Real world outcomes in elderly women with HER2-positive advanced breast cancer
Presenter: Nicole Evans
Session: e-Poster Display Session
52P - Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study)
Presenter: Yookija Kang
Session: e-Poster Display Session
53P - Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2- metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression
Presenter: Indunil Weerasena
Session: e-Poster Display Session
54P - Platinum-based chemotherapy in advanced breast cancer (ABC): Real-world outcome from a tertiary cancer centre in India
Presenter: Indhuja Vijesh
Session: e-Poster Display Session
55P - Eribulin in heavily pretreated metastatic breast cancer: A real-world data from India
Presenter: Tanmoy Mandal
Session: e-Poster Display Session
56P - Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
Presenter: Yiqi Yang
Session: e-Poster Display Session
57P - Therapeutic vulnerability of malignant phyllodes tumour to pazopanib identified through a novel patient-derived xenograft and cell line model
Presenter: Dave Ng
Session: e-Poster Display Session
58P - Survival benefit of local treatments in breast cancer with lung metastasis: Results from a large retrospective study
Presenter: Yimeng Chen
Session: e-Poster Display Session
59P - The impact of site of metastasis on overall survival in indigenous and non-indigenous patients of Western Australia with breast cancer
Presenter: Azim Khan
Session: e-Poster Display Session
60P - Risk factors of bone metastasis and skeletal-related events in high-risk breast cancer patients
Presenter: Sumadi Lukman Anwar
Session: e-Poster Display Session